Astrana Health Inc (ASTH)vsAstraZeneca PLC (AZN)
ASTH
Astrana Health Inc
$37.99
+0.37%
HEALTHCARE · Cap: $1.87B
AZN
AstraZeneca PLC
$185.95
-0.83%
HEALTHCARE · Cap: $282.69B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 1614% more annual revenue ($60.44B vs $3.53B). AZN leads profitability with a 17.2% profit margin vs 0.9%. AZN trades at a lower P/E of 27.5x. AZN earns a higher WallStSmart Score of 64/100 (C+).
ASTH
Buy56
out of 100
Grade: C
AZN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+89.9%
Fair Value
$188.57
Current Price
$37.99
$150.58 discount
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 55.6% year-over-year
Earnings expanding 110.1% YoY
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
ROE of 3.8% — below average capital efficiency
0.9% margin — thin
Operating margin of 3.0%
Moderate valuation
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ASTH
The strongest argument for ASTH centers on Revenue Growth, EPS Growth, Price/Book. Revenue growth of 55.6% demonstrates continued momentum.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : ASTH
The primary concerns for ASTH are Market Cap, Return on Equity, Profit Margin. A P/E of 61.7x leaves little room for execution misses. Thin 0.9% margins leave little buffer for downturns.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Key Dynamics to Monitor
ASTH profiles as a hypergrowth stock while AZN is a mature play — different risk/reward profiles.
ASTH carries more volatility with a beta of 0.99 — expect wider price swings.
ASTH is growing revenue faster at 55.6% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 56/100), backed by strong 17.2% margins and 12.5% revenue growth. ASTH offers better value entry with a 89.9% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Astrana Health Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. The company is headquartered in Alhambra, California.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?